

Broad Clinical Development Program for Cobimetinib

As of our Q2 2017 financial results call, August 2, 2017. All listed cobimetinib clinical trials are sponsored by Roche/Genentech. Not a full list of studies; see ClinicalTrials.gov for a comprehensive list.

Indication	Combination Regimen	Status Update
Metastatic or Unresectable Locally Advanced Melanoma		
First-line BRAF mutation-positive	+ atezolizumab + vemurafenib	Phase 3 (IMspire150 TRILOGY) began enrolling Q1 2017
First-line BRAF wild-type	+ atezolizumab	Phase 3 (IMspire170) expected to begin enrolling Q3 2017
Colorectal Cancer		
Third-line advanced or metastatic disease	+ atezolizumab	Phase 3 (IMblaze370) completed enrollment in Q1 2017
Second/third-line metastatic disease	+ atezolizumab + bevacizumab	Phase 1
Breast Cancer		
First-line metastatic triple negative disease	+ taxane +/- atezolizumab	Phase 2 (COLET)
Pancreatic Cancer		
Metastatic pancreatic ductal adenocarcinoma	+ atezolizumab	Phase 1b/2 (One arm of a randomized umbrella study)